DDInter948 DDInter1955
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Zafirlukast {u} (Compound) resembles {v} (Compound) Tolvaptan
Zafirlukast {u} (Compound) treats {v} (Disease) asthma
Zafirlukast {u} (Compound) binds {v} (Gene) CYSLTR2
Zafirlukast {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Zafirlukast {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Zafirlukast {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Zafirlukast (Compound) resembles Tolvaptan (Compound)
Zafirlukast (Compound) treats asthma (Disease)
Zafirlukast (Compound) binds CYSLTR2 (Gene)
Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Zafirlukast (Compound) causes Hyperbilirubinaemia (Side Effect)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide